Latest TB scientific highlights:
- Baylor College of Medicine: TB induces premature cellular aging
In а study published in Aging, researchers found that the cells of humans and animals that have recovered from TB had prematurely aged up to 12 to 14 years. ‘It’s possible that this premature cellular aging is one reason why survivors of TB have a higher risk of mortality, sometimes a three-fold higher.’
In а study published in Cell Chemical Biology, researchers identified a novel target for TB ‘host-directed therapy’ and delivered a newly designed chemical compound with drug-like properties that could be used to treat the disease in combination with existing antibiotics.
According to a study published in PLOS Pathogens, the immune response mounted against TB in mice prevents them from developing COVID-19.
- Infectious Disease Advisor: Outcomes of concomitant bedaquiline and delamanid in patients with multidrug-resistant TB
According to a study published in Clinical Infectious Diseases, concomitant treatment with bedaquiline and delamanid was determined to be safe and effective and did not increase the risk for cardiotoxicity in patients with multidrug- and rifampicin-resistant TB.
- Infectious Disease Advisor: Meropenem plus clavulanate and rifampin for treatment of drug-resistant TB
A study, published in the American Journal of Respiratory and Critical Care Medicine, called into question the recommendation for meropenem with amoxicillin and clavulanate to be used as a second-line therapy for drug-resistant TB.
For more TB news, check out the latest edition of the TB Online Weekly Newsletter (#10, 30 March 2022).
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.